Mattia Garutti, MD, medical oncologist, Unit of Clinical Oncology, Centro di Riferimento Oncologico di Aviano, Aviano, Italy, discusses the potential shift to neoadjuvant therapy in melanoma.
Mattia Garutti, MD, medical oncologist, Unit of Clinical Oncology, Centro di Riferimento Oncologico di Aviano, Aviano, Italy, discusses the potential shift to neoadjuvant therapy in melanoma.
Posted in Melanoma News, Health Professionals, Video Reports
Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the design of the ?phase 3 CheckMate-067 trial in advanced melanoma.
Posted in Melanoma News, Health Professionals, Video Reports
Alexander M. M. Eggermont, MD, PhD, professor of oncology, University of Paris-Sud, professor of oncological surgery, chair, International Research Network on Cancer, Erasmus University of Rotterdam, Joseph Maisin Honorary Chair of Oncological Surgery, Louvain Catholic University, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, ?evaluating adjuvant pembrolizumab (Keytruda) versus placebo, in advanced melanoma.
Posted in Melanoma News, Health Professionals, Video Reports
Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ?the potential utility of pembrolizumab (Keytruda) in combination with selinexor ?(Xpovio) in advanced melanoma.
Posted in Melanoma News, Health Professionals, Video Reports